Exploring the association between selective serotonin reuptake inhibitors and rhabdomyolysis risk based on the FDA pharmacovigilance database.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
28 07 2023
28 07 2023
Historique:
received:
11
05
2023
accepted:
26
07
2023
medline:
31
7
2023
pubmed:
29
7
2023
entrez:
28
7
2023
Statut:
epublish
Résumé
Rhabdomyolysis is a syndrome potentially fatal and has been associated with selective serotonin reuptake inhibitors (SSRIs) treatment in a few case reports. Herein, we purpose to establish the correlation between SSRIs use and rhabdomyolysis using the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS) database. We conducted an analysis on reports that were submitted to the FAERS database during the period between January 1, 2004, and December 31, 2022. Four algorithms, including reporting odds ratio (ROR), proportional reporting ratio (PRR), Bayesian confidence propagation neural network (BCPNN), and empirical Bayes geometric mean (EBGM), were employed to quantify the signals of rhabdomyolysis associated with SSRIs. In total, 16,011,277 non-duplicated reports were obtained and analyzed. Among 33,574 reports related to rhabdomyolysis, SSRIs were classified as primary suspected drug in 889 cases. Disproportionality analysis identified a positive signal between rhabdomyolysis and SSRIs (ROR: 2.86, 95% CI 2.67-3.05; PRR: 2.84, χ
Identifiants
pubmed: 37507539
doi: 10.1038/s41598-023-39482-y
pii: 10.1038/s41598-023-39482-y
pmc: PMC10382477
doi:
Substances chimiques
Selective Serotonin Reuptake Inhibitors
0
Fluvoxamine
O4L1XPO44W
Paroxetine
41VRH5220H
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
12257Informations de copyright
© 2023. The Author(s).
Références
Pharmacol Res. 2018 Oct;136:194-204
pubmed: 30196103
Neurol Int. 2021 Aug 05;13(3):387-401
pubmed: 34449705
Drug Healthc Patient Saf. 2021 Nov 08;13:211-219
pubmed: 34795533
N Engl J Med. 2009 Jul 2;361(1):62-72
pubmed: 19571284
J Clin Psychopharmacol. 2015 Feb;35(1):108-9
pubmed: 25360882
BMC Pharmacol Toxicol. 2023 Mar 31;24(1):22
pubmed: 37004083
Lancet Psychiatry. 2021 Dec;8(12):1071-1082
pubmed: 34801129
Curr Drug Saf. 2015;10(3):234-50
pubmed: 26219291
Crit Care. 2005 Apr;9(2):158-69
pubmed: 15774072
J Clin Psychopharmacol. 2019 Nov/Dec;39(6):628-633
pubmed: 31688388
Asian J Psychiatr. 2021 Dec;66:102891
pubmed: 34717111
Pharmacopsychiatry. 2022 Jan;55(1):24-29
pubmed: 34875696
Neuromuscul Disord. 2014 Aug;24(8):651-9
pubmed: 24946698
Forensic Toxicol. 2017;35(2):369-375
pubmed: 28890736
Eur J Intern Med. 2007 Mar;18(2):90-100
pubmed: 17338959
Lancet. 1997 May 31;349(9065):1602
pubmed: 9174567
Ann Intensive Care. 2020 Mar 2;10(1):27
pubmed: 32124091
Chem Res Toxicol. 2014 Mar 17;27(3):421-32
pubmed: 24422454
Crit Care. 2016 Jun 15;20(1):135
pubmed: 27301374
Int J Clin Pharm. 2018 Aug;40(4):758-763
pubmed: 29248988
J Neurochem. 2022 Jul;162(1):39-59
pubmed: 34978711
Clin Ther. 2019 Sep;41(9):1755-1766
pubmed: 31371035
J Trauma. 2006 Feb;60(2):407-9; discussion 409
pubmed: 16508505
Clin Ther. 2007 Jan;29(1):172-6
pubmed: 17379057
Am J Ther. 2016 Mar-Apr;23(2):e561-5
pubmed: 25581857
Eur J Hosp Pharm. 2022 Dec 2;:
pubmed: 36460460
Med Intensiva. 2008 Oct;32(7):365-6
pubmed: 18842231
JAMA Intern Med. 2013 Oct 28;173(19):1821-8
pubmed: 24000014
Life (Basel). 2020 Aug 05;10(8):
pubmed: 32764444
BMJ Case Rep. 2018 Oct 8;2018:
pubmed: 30301727
Clin Pharmacol Ther. 2014 May;95(5):496-8
pubmed: 24448476
Sci Total Environ. 2022 Jul 10;829:154656
pubmed: 35318057
Trauma Surg Acute Care Open. 2022 Jan 27;7(1):e000836
pubmed: 35136842